Key result
Azilsartan medoxomil demonstrates effective blood pressure reduction with a favorable safety profile in hypertension.
Why the study?
Azilsartan medoxomil is a novel angiotensin AT1 receptor antagonist with promising antihypertensive activity and safety that has been evaluated in phase III trials for essential hypertension.
Does azilsartan medoxomil improve blood pressure in patients with essential hypertension?
Does azilsartan medoxomil improve blood pressure in patients with essential hypertension?
Azilsartan medoxomil is an approved angiotensin receptor blocker with promising antihypertensive activity and a good safety profile for patients with essential hypertension.
May offer an additional ARB option in hypertension; leaves open comparative effectiveness versus other agents.
The use of angiotensin receptor blockers (ARBs) represents a favorable approach for the control of blood pressure in patients with hypertension. Azilsartan medoxomil, a prodrug that undergoes rapid hydrolysis to its active moiety azilsartan, is an angiotensin AT(1) receptor antagonist with promising antihypertensive activity and a good safety profile. The agent has been evaluated as monotherapy and in combination with amlodipine or chlorthalidone in phase III trials in patients with essential hypertension. In 2011, azilsartan medoxomil was approved in the U.S. for the treatment of hypertension.
No takes yet. Share an insight, caveat, or question.
Stauros Vasiliou (2011) conducted a review in hypertension. Azilsartan medoxomil was evaluated. Azilsartan medoxomil is an angiotensin receptor blocker with promising antihypertensive activity and a good safety profile that was approved in the U.S. in 2011 for the treatment of hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: